Phase 2 Bladder Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have recurring low-grade bladder cancer (a type that has not spread into the bladder muscle) that has come back after previous treatment
- People whose bladder tumor was visible during a camera examination of the bladder (cystoscopy) within the 12 weeks before starting the trial
- People whose bladder cancer is considered intermediate-risk, meaning at least one of the following applies: they have multiple tumors; the cancer has come back more than once within a year; the cancer came back within a year of first being diagnosed; there is a single tumor larger than 3 cm; or previous bladder treatments have not worked
- People who are reasonably well and able to carry out daily activities, based on a standard health rating scale assessed within 14 days before starting the trial (confirm with trial site)
Who may not be able to join:
- People who have been newly diagnosed with low-grade bladder cancer for the first time
- People who have had, or currently have, a more aggressive or advanced form of bladder cancer, including high-grade bladder cancer, cancer that has grown into the bladder muscle, or cancer that has spread to other parts of the body
- People who have a condition that prevents them from urinating normally, or from holding their urine for one to two hours
- People who have a history of serious dry eye conditions, serious eyelid gland disease, or serious corneal disease that affects how the eye heals
- People who have active inflammatory bowel disease (such as Crohn's disease or ulcerative colitis) requiring medications that suppress the immune system, or who have a history of these conditions or chronic diarrhoea
- People who have serious, uncontrolled heart or blood vessel disease
- People who have another cancer that is still growing or has needed active treatment within the past three years
- People who have a history of, or currently have, a non-infectious lung condition involving inflammation of the lung tissue that required steroid treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, Merck Sharp & Dohme LLC
Phone: 1-888-577-8839
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants with Dose Limiting Toxicity (DLT); Number of Participants Experiencing an Adverse Event (AE); Number of Participants Discontinuing Study Treatment due to an Adverse Event (AE)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.